1910 Genetics

1910 Genetics is a Boston, Massachusetts based biotechnology company that’s shaking up drug discovery by integrating artificial intelligence (AI), computational tools, and biological automation. Founded in 2018 by Jen Nwankwo, Ph.D., the company aims to slash the time and cost of developing new medicines while boosting success rates—addressing a major pain point in the pharmaceutical industry, where R&D timelines often stretch over a decade and costs can hit billions per drug. Its dual-focus platform targets both small molecule and protein therapeutics, a rare combo in the AI-driven drug discovery space. The company’s pipeline targets tough diseases like neurological disorders, autoimmune conditions, and cancer, while also offering its tech as a service to pharma giants. Its latest AI model, CANDID-CNS™, launched in October 2024, predicts blood-brain barrier permeability with an 83% success rate, outstripping industry standards for CNS drug development. The company formed strategic partnerships with Accenture and Microsoft, tapping Azure Quantum Elements to scale its platform for biopharma clients.

‍